Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

Evan Seigerman, head of healthcare research at BMO Capital Markets, joins 'Money Movers' to discuss Pfizer and Merck's latest ...

Pfizer posted adjusted earnings of 66 cents per share, beating the 57 cents forecast by analysts, News.Az reports, citing foreign ...

Stock market update: futures rise after Wall Street sell-off as investors digest Amazon earnings and watch MSTR, Pfizer, HIMS ...

What does a successful retirement look like? If it means financial security through steady income sources, then you can get ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Which of the highest-yielding healthcare stocks are value traps or golden opportunities?

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness.